{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-21-004749","form_type":"8-K","ticker":"RCUS","cik":"0001724521","company_name":"Arcus Biosciences, Inc.","filed_at":"2021-11-18T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.844238+00:00","generated_at":"2026-06-28T07:03:30.874066+00:00","sec_items":["1.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Gilead exercises options on three Arcus programs for $725M; co-development and profit sharing","bullets":["Gilead paid $725M in option fees to exercise rights to three Arcus programs: anti-TIGIT, adenosine antagonist, and CD73.","Companies will co-develop and equally share US profits/losses; Gilead gets ex-US rights with mid-teens to low-twenties royalties.","Two new research targets added; Gilead can option each for $60M after IND-enabling activities; royalties high-single to low-double digits.","The existing $100M 2022 Continuation Payment will be eliminated if all three programs close; reduced if fewer close.","Transaction subject to HSR antitrust review."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-21-004749","json":"https://secwatch.observer/filing/0000950170-21-004749.json","markdown":"https://secwatch.observer/filing/0000950170-21-004749.md","text":"https://secwatch.observer/filing/0000950170-21-004749.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1724521/000095017021004749/0000950170-21-004749-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1724521/000095017021004749/rcus-20211117.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T07:03:30.874066+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}